Hypoplastic Left Heart Syndrome Clinical Trial
Official title:
Phase IIb Study of Intramyocardial Injection of Autologous Umbilical Cord Blood Derived Mononuclear Cells During Stage II Surgical Repair of Right Ventricular Dependent Variants of Hypoplastic Left Heart Syndrome (AutoCell-S2)
Verified date | May 2023 |
Source | ReGen Theranostics, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Researchers want to better understand what happens to the heart when the stem cells are injected directly into the muscle of the right side of the heart during the Stage II palliative surgery for single ventricle patients with hypoplastic left heart syndrome (HLHS) or HLHS variant. Researchers want to see if there are changes in the heart's structure/function following this stem cell-based therapy and compared to children that have not had cell-based therapy.
Status | Active, not recruiting |
Enrollment | 95 |
Est. completion date | February 2026 |
Est. primary completion date | May 22, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A to 12 Months |
Eligibility | Inclusion Criteria: - Diagnosis of HLHS or HLHS variant with single right ventricular dependent CHD having undergone Stage I surgical repair and undergoing Stage II surgical repair. - Less than 13 months of age at time of Stage II surgical repair - Previous participation in the UCB collection protocol with autologous UCB-MNC product that is acceptable for use (treatment arm only) Exclusion Criteria: - History of DMSO reaction (treatment arm only). - Parent(s) and/or legal guardian(s) unwilling to have their child participate or unwilling to follow the study procedures. - Severe chronic diseases at the discretion of the treating physician. - Extensive extra-cardiac syndromic features. - Known history of cancer. - Any of the following complications of his/her congenital heart disease: 1. Any condition requiring urgent, or unplanned interventional procedure within 15 days prior to Stage II surgical repair, unless complete and full cardiac recovery is documented by site investigator 2. Severe pulmonary hypertension (reported in the medical record as >70% systemic pressure) 3. Other clinical concerns as documented by a site investigator that would predict (more likely to happen than not to happen) a risk of severe complications or very poor outcome, not directly related to the stem cell product or its injection procedure, during or after Stage II surgical repair. |
Country | Name | City | State |
---|---|---|---|
United States | Children's Hospital Colorado | Aurora | Colorado |
United States | Children's of Alabama | Birmingham | Alabama |
United States | Cincinnati Children's Hospital and Medical Center | Cincinnati | Ohio |
United States | Children's Hospital of Los Angeles | Los Angeles | California |
United States | Children's Hospitals of Minnesota | Minneapolis | Minnesota |
United States | Ocshner Medical Center | New Orleans | Louisiana |
United States | Oklahoma University Medical Center | Oklahoma City | Oklahoma |
United States | Children's Hospital of Philadelphia | Philadelphia | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Timothy J Nelson, MD, PhD | Children's Hospital Colorado, Children's Hospital Los Angeles, Children's Hospital Medical Center, Cincinnati, Children's Hospital of Philadelphia, Children's Hospitals and Clinics of Minnesota, Children's of Alabama, Ochsner Health System, University of Oklahoma |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Right Ventricular Cardiac Function measured by apical fractional area change (FAC) | Right ventricular cardiac function as measured by echocardiogram that includes studies for apical fractional area change (FAC). Measured by percent. | baseline, 3 months post-Stage II surgery | |
Primary | Change in Right Ventricular Cardiac Function measured by circumferential strain. | Right ventricular cardiac function as measured by echocardiogram that includes studies for circumferential strain. Measured by percent. | baseline, 3 months post-Stage II surgery | |
Primary | Change in Right Ventricular Cardiac Function measured by longitudinal strain. | Right ventricular cardiac function as measured by echocardiogram that includes studies for longitudinal strain. Measured by percent. | baseline, 3 months post-Stage II surgery | |
Primary | Change in Right Ventricular Ejection Fraction | Right ventricular ejection fraction as measured by echocardiogram. Ejection Fraction is calculated by the volume of blood in the heart during systole and diastole. It is the percentage of the volume in the ventricle ejected during a cardiac cycle. Measured by percent. The normal ejection fraction is 55 to 75 percent. | baseline, 12 months post-Stage II surgery | |
Secondary | Change in ejection fraction | Ejection fraction as measured by echocardiogram. Ejection Fraction is calculated by the volume of blood in the heart during systole and diastole. It is the percentage of the volume in the ventricle ejected during a cardiac cycle. Measured by percent. The normal ejection fraction is 55 to 75 percent. | baseline pre-op, hospital discharge from Stage II surgery (an average of 1-6 weeks) | |
Secondary | Cumulative days of hospitalization | Cumulative days of hospitalization per patient following discharge for the Stage II surgical repair. | 1, 3-months post Stage II surgery | |
Secondary | Change in weight | Weight as measured by scale provided as part of standard of care by subject's provider. Measured at home by subject's caregiver using the same scale for every home measurement of body weight. Caregivers will be instructed by the site to use the same scale for every home measurement of body weight. Scales will vary based on the institution's standard name/type used. | 3-months post Stage II surgery | |
Secondary | Change in heart rate | Heart rate as measured at home by subject's caregiver as standard of care per subject's provider. Caregivers will be instructed by the site staff on the best way to perform. | 3-months post Stage II surgery | |
Secondary | Change in oxygen saturation | Oxygen saturation as measured at home by subject's caregiver using the pulse oximetry device provided as standard of care by subject's provider. Caregivers will be instructed by the site to use the same pulse oximetry device for every home measurement of oxygen saturation. | 3-months post Stage II surgery | |
Secondary | Change in weight | Weight as measured by scale provided as part of standard of care by subject's provider. Measured at home by subject's caregiver using the same scale for every home measurement of body weight. Caregivers will be instructed by the site to use the same scale for every home measurement of body weight. Scales will vary based on the institution's standard name/type used. | baseline, every 6 months post-Stage II surgery | |
Secondary | Change in heart failure medication | Changes in heart failure medications will be recorded by caregiver on the concomitant medication diary throughout the subject's participation in the study starting at the time of consent. | baseline, every 6 months post-Stage II surgery | |
Secondary | Change in arrhythmia medication | Changes in arrhythmia medication will be recorded by subject's caregiver on the concomitant medication diary throughout the subject's participation in the study starting at the time of consent. | baseline, every 6 months post-Stage II surgery | |
Secondary | Stage III surgical repair | The number of research subjects eligible for Stage III surgical repair | Stage III surgery pre-op, approx. 4 years | |
Secondary | Total time until listed for cardiac transplantation | The number of days between Stage II surgery and listed on cardiac transplantation list. | up to Stage III surgery pre-op, approx. 4 years | |
Secondary | Change in right ventricular function | Right ventricular ejection fraction as measured by echocardiogram, and cardiac catheterization. Ejection Fraction is calculated by the volume of blood in the heart during systole and diastole. It is the percentage of the volume in the ventricle ejected during a cardiac cycle. Measured by percent. The normal ejection fraction is 55 to 75 percent. | baseline, Stage III surgery pre-op | |
Secondary | Total time until death | The number of days between Stage II surgery and death occurrence | approx 4 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01215240 -
Prophylactic Peritoneal Dialysis Decreases Time to Achieve a Negative Fluid Balance After the Norwood Procedure
|
N/A | |
Completed |
NCT00513240 -
Erythropoetin Neuroprotection for Neonatal Cardiac Surgery
|
Phase 1/Phase 2 | |
Withdrawn |
NCT00156455 -
Sleep Disordered Breathing in Children With Single Ventricle Physiology
|
N/A | |
Terminated |
NCT01445041 -
Safety and Feasibility Study of Umbilical Cord Blood Cells for Infants With Hypoplastic Left Heart Syndrome
|
Phase 1 | |
Recruiting |
NCT04581668 -
Impact of NAVA Ventilation on Brain Oxygenation and Perfusion in Children With Congenital Heart Disease
|
N/A | |
Completed |
NCT01708863 -
A Prospective Study of Patients With Hypoplastic Left Heart Syndrome (HLHS) Following Stage II Surgical Palliation
|
||
Completed |
NCT01736956 -
Fetal Intervention for Aortic Stenosis and Evolving Hypoplastic Left Heart Syndrome
|
N/A | |
Recruiting |
NCT03406884 -
The CHILD Trial: Hypoplastic Left Heart Syndrome Study.
|
Phase 1 | |
Not yet recruiting |
NCT06461676 -
Study of Intramyocardial Injection of Ventrix Bio Extracellular Matrix (VentriGel) to Assess the Safety and Feasibility in Pediatric Patients With Hypoplastic Left Heart Syndrome (HLHS)
|
Phase 1 | |
Active, not recruiting |
NCT03079401 -
Mesoblast Stem Cell Therapy for Patients With Single Ventricle and Borderline Left Ventricle
|
Phase 1/Phase 2 | |
Completed |
NCT02306057 -
Fluid Balance in Children Undergoing Fontan Surgery
|
N/A | |
Terminated |
NCT01107990 -
Global and Regional Myocardial Strain and Power Output In Patients With Single Ventricles Using Novel MRI Techniques
|
||
Completed |
NCT01883076 -
Safety Study of Autologous Umbilical Cord Blood Cells for Treatment of Hypoplastic Left Heart Syndrome
|
Phase 1 | |
Completed |
NCT04056416 -
Physical Activity Promotion in Children and Adolescents With Single Ventricle Physiology (MedBike)
|
N/A | |
Completed |
NCT01656941 -
Genetic Determinants of Congenital Heart Disease Outcomes
|
||
Completed |
NCT00464100 -
Near-infrared Spectroscopy (NIRS) Neurodevelopmental Outcomes
|
||
Recruiting |
NCT04925024 -
Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Syndrome (HLHS): A Phase IIb Clinical Trial.
|
Phase 2 | |
Recruiting |
NCT02781922 -
Cardiac Stem/Progenitor Cell Infusion in Univentricular Physiology (APOLLON Trial)
|
Phase 3 | |
Completed |
NCT01582529 -
SVRII Family Factors Study
|
||
Completed |
NCT00974025 -
Impact of Vitamin C on Endothelial Function and Exercise Capacity in Fontan-Palliated Patients
|
N/A |